Data / Drug companies / Granules India Limited
Granules India Limited: 156 products in the FDA NDC directory, labeler code 62207
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Granules India Limited (labeler code 62207) lists 156 products in the FDA National Drug Code Directory, covering 21 finished drugs by generic name. By type: 53 drugs for further processing, 44 bulk ingredients. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 28, 2026.
The request: Watch Granules India Limited (FDA labeler code 62207): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 62207
- Products in commercial distribution
- 156
- Packages
- 435
- Finished drugs by generic name
- 21
- Prescription products
- 26
- Over the counter products
- 33
- Controlled substance products
- Schedule II 1
- Flagged as original packager
- 31 of 31 products that carry the flag
- Started marketing in the last 12 months
- 13
- Earliest marketing start
- May 12, 2009
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 59 | 37.8% |
| Drugs for further processing | 45 | 28.8% |
| Bulk ingredients | 37 | 23.7% |
| Export only | 15 | 9.6% |
Products by type
| Type | Products | Share |
|---|---|---|
| Drugs for further processing | 53 | 34% |
| Bulk ingredients | 44 | 28.2% |
| Over the counter drugs | 33 | 21.2% |
| Prescription drugs | 26 | 16.7% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Powder | 77 | 49.4% |
| Tablet | 40 | 25.6% |
| Tablet, extended release | 16 | 10.3% |
| Tablet, film coated | 13 | 8.3% |
| Granule | 3 | 1.9% |
| Tablet, coated | 3 | 1.9% |
| Capsule, extended release | 2 | 1.3% |
| Capsule | 1 | 0.6% |
| Capsule, gelatin coated | 1 | 0.6% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Resmetirom | 62207-998 | Powder | Bulk ingredients | October 28, 2026 |
| Elacestrant dihydrochloride | 62207-997 | Powder | Bulk ingredients | August 21, 2026 |
| Acetaminophen | 62207-892 | Tablet, extended release | Generic drugs (ANDA) | April 16, 2026 |
| Gabapentin | 62207-996 | Powder | Bulk ingredients | March 30, 2026 |
| Serdexmethylphendiate chloride | 62207-027 | Powder | Bulk ingredients | February 27, 2026 |
| Calcium oxybate | 62207-994 | Powder | Drugs for further processing | December 26, 2025 |
| Potassium oxybate | 62207-993 | Powder | Drugs for further processing | December 26, 2025 |
| Trazodone hydrochloride (common lubricated blend) | 62207-615 | Granule | Export only | December 24, 2025 |
| Magnesium oxybate | 62207-995 | Powder | Drugs for further processing | December 1, 2025 |
| Sodium oxybate | 62207-992 | Powder | Drugs for further processing | December 1, 2025 |
| Empagliflozin | 62207-026 | Powder | Bulk ingredients | December 1, 2025 |
| Dapagliflozin | 62207-021 | Powder | Drugs for further processing | November 14, 2025 |
| Olmesartan medoxomil | 62207-018 | Powder | Bulk ingredients | November 10, 2025 |
| Metoprolol Succinate | 62207-130 | Tablet, extended release | Generic drugs (ANDA) | August 1, 2025 |
| Ruxolitinib phosphate | 62207-991 | Powder | Drugs for further processing | July 7, 2025 |
| Ruxolitinib hydrochloride | 62207-990 | Powder | Drugs for further processing | July 7, 2025 |
| Viloxazine hydrochloride | 62207-989 | Powder | Drugs for further processing | July 7, 2025 |
| Paracetamol ph.eur | 62207-934 | Powder | Bulk ingredients | April 14, 2025 |
| Losartan Potassium | 62207-743 | Tablet | Generic drugs (ANDA) | March 18, 2025 |
| Losartan Potassium | 62207-741 | Tablet | Generic drugs (ANDA) | March 18, 2025 |
| Avatrombopag maleate | 62207-025 | Powder | Drugs for further processing | March 12, 2025 |
| Acetaminophen | 62207-078 | Tablet | Export only | January 2, 2025 |
| Acetaminophen | 62207-234 | Tablet, extended release | Export only | January 1, 2025 |
| Acetaminophen extra strength | 62207-050 | Tablet | Export only | January 1, 2025 |
| Acetaminophen | 62207-044 | Tablet | Export only | January 1, 2025 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.